Introduction {#s1}
============

The heme-containing plant enzyme horseradish peroxidase (HRP; EC 1.11.1.7) is a Class III peroxidase catalyzing the oxidation of various substrates (e.g., amines, aromatic phenols, indoles, phenolic acids and sulfonates) using hydrogen peroxide (H~2~O~2~) as oxidant. Horseradish peroxidase exists in at least 19 different isoenzyme forms in the horseradish root (*Armoracia rusticana*), of which isoenzyme C1A is the most abundant and thus the most studied one (e.g., [@CWU047C9]; [@CWU047C48]; [@CWU047C47]; [@CWU047C4]; [@CWU047C23]; [@CWU047C41]). It is a 34 kDa monomeric oxidoreductase containing a heme-group as well as two Ca^2+^-ions as prosthetic groups. The crystal structure of HRP C1A led to the identification of nine N-glycosylation sites of the Asn-X-Ser/Thr type, where X can be any amino acid but proline, of which eight are occupied when the enzyme is expressed in plant ([@CWU047C40]), which is why the molecular mass of HRP C1A increases from 34 to ∼44 kDa ([@CWU047C47]; [@CWU047C41]). Due to glycosylation and the presence of both, the heme-group and disulfide bridges, the recombinant production and subsequent preparative purification of HRP has proven to be very difficult ([@CWU047C40]; [@CWU047C12]; [@CWU047C26]; [@CWU047C43]), which is why HRP is still mainly isolated from plant ([@CWU047C26]). However, HRP preparations from plant describe a mixture of isoenzymes, which seasonally varies in composition and concentration, and yields are extremely low ([@CWU047C19]; [@CWU047C20]; [@CWU047C39]). Since HRP is a versatile enzyme used in numerous, quite diverse industrial and medical applications, such as waste water treatment, fine chemical synthesis, immunoassays, biosensors and coupled enzyme assays (e.g., [@CWU047C25]), the controllable recombinant production and subsequent efficient purification of single HRP isoenzymes is highly desired. Thus, we have not only investigated and improved the recombinant production of the isoenzyme HRP C1A with *Pichia pastoris* in the past few years ([@CWU047C6],[@CWU047C7]; [@CWU047C22]; [@CWU047C52]; [@CWU047C44]), but also developed an efficient downstream process for the hypermannosylated enzyme recombinantly derived from this yeast ([@CWU047C43]; [@CWU047C24]). However, for medical applications where HRP is conjugated to antibodies, like antibody-directed enzyme-prodrug therapy ([@CWU047C11]; [@CWU047C51]) and medical diagnostics ([@CWU047C37]; [@CWU047C16]; [@CWU047C34]; [@CWU047C8]), the degree of glycosylation of HRP is of utmost importance, since not only the stability of the enzyme but also the conjugation with antibodies is expected to change with varying glycosylation. Besides, the untrimmed yeast-derived high-mannose containing glycosylation can trigger immune responses in humans (personal communication with Dr. Lisa Folkes; Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford).

Obviously, the availability of an enzyme without or at least with reduced surface glycosylation would solve abovementioned problems. However, the biological role and importance of glycans for plant peroxidases is still not completely understood and is topic of numerous studies in glycobiology. So far, some studies report stabilizing effects of the glycans ([@CWU047C32]; [@CWU047C50]), whereas other studies do not show such effects ([@CWU047C10]; [@CWU047C36]). In 1990, [@CWU047C40]) were able to produce active and correctly folded HRP without any glycans in *Escherichia coli*. In a following study, Tams and Welinder analyzed the importance of the glycosylation for HRP in more detail ([@CWU047C46]). They showed that the removal of most of the glycans, except the *N*-acetylglucosamine residues, by a mild chemical deglycosylation with trifluoromethanesulfonic acid resulted in a fully active, but less stable enzyme ([@CWU047C45], [@CWU047C46]). Both studies showed that glycans on the surface of HRP affect the physicochemical properties of the enzyme but are not required for catalytic activity. However, chemical deglycosylation only left 60% of HRP active and also describes a quite cumbersome procedure ([@CWU047C45], [@CWU047C46]), which is why it is not a useful method to obtain unglycosylated HRP. Although recombinant proteins from *P. pastoris* can also be deglycosylated enzymatically ([@CWU047C38]; [@CWU047C21]), also this option has to be reconsidered, since (1) enzymatic deglycosylation is only quantitative when the target protein is denatured and (2) the additional endo-glycosidases have to be removed again to obtain pure product. Another way to control and reduce the complexity of native yeast-like glycosylation on glycoproteins secreted from *P. pastoris* is through glyco-engineering ([@CWU047C5]; [@CWU047C14]; [@CWU047C49]; [@CWU047C15]). A key event in such engineering is the knockout of the OCH1 gene, which initiates outer-chain elongation, leading to hypermannosylation. However, in a previous study, where we knocked out this gene, we observed that HRP with reduced glycan complexity possessed hampered downstream processing and that the glyco-engineered *P. pastoris* strains generated were physiologically impaired, impeding efficient production processes ([@CWU047C23]).

Consequently, the last resort to efficiently produce HRP with a reduced amount of surface glycosylation is to glyco-engineer the enzyme itself. In a recent study, two selected Asn residues of HRP were mutated to Asp to analyze effects on the stability of the enzyme and to produce more properly folded HRP in *E. coli* ([@CWU047C2]). [@CWU047C2]) showed that introducing the mutations Asn13Asp and Asn268Asp did not just affect the production of HRP in *E. coli*, but also increased the catalytic constants as well as the thermal stability. These results did not only underline the possibility of obtaining active and correctly folded HRP with reduced glycosylation but also showed that mutating the glycosylation sites may even have beneficial effects on catalytic activity and stability.

In the present study, we generated a glyco-variant library of HRP C1A exchanging all the eight Asn serving as glycosylation sites by the structurally similar amino acids Asp, Gln or Ser. We did not only investigate the effects of the single mutations on enzyme activity and stability but also on protein purification following an integrated bioprocess technology approach. After determining the most suitable mutation at the single N-glycosylation sites, we physiologically characterized the respective *P. pastoris* strains in the controlled environment of a bioreactor. A two-step purification procedure, where both chromatography steps were performed in the flow-through mode, enabled us to recover purified HRP glyco-variants for subsequent biochemical characterization. Based thereon, we combined the most suitable mutations to potentially obtain an unglycosylated, active HRP variant suitable for medical applications. Summarizing, we conducted an integrated bioprocess study and present the bioprocess technological and biochemical results for the HRP C1A glyco-variant library.

Results and discussion {#s2}
======================

Screening procedure {#s2a}
-------------------

Every transformation into *P. pastoris* CBS7435 Mut^S^ yielded several dozens of transformants. We randomly picked five transformants per mutation and screened them for cell growth and production of active HRP in shake flasks. With only few exceptions, all the picked transformants produced active HRP; however, on average only three of five showed comparable growth and productivity. PCR analysis confirmed the presence of the target gene in the genome of *P. pastoris*. Although we did not analyze the exact number of gene integration events by real-time polymerase chain reaction, we assumed the integration of a comparable amount of gene copies into the yeast genome due to the fact that we always transformed the same amount of linearized vector DNA into the *P. pastoris* cells (i.e., 2 μg DNA). We had observed such a correlation in a previous study ([@CWU047C22]). Although we did not check for the exact integration site of the target gene in the host genome, we ascribe the observed differences in protein production during the screening procedure to a fair amount of non-homologous recombination of the transformed HRP C1A gene into the genome of *P. pastoris* ([@CWU047C31]), most likely at different loci in the chromosome, which consequently influences the accessibility of the transcription machinery to the transformed gene ([@CWU047C22]). In Table [I](#CWU047TB1){ref-type="table"}, we compared the growth of the best transformant per mutation as well as the specific activity and thermal stability of the produced HRP C1A glyco-variants. Although diagnostic applications are normally not performed at 60°C, we determined the stability of HRP at this temperature since we observed nice differences for the glyco-variants at this temperature and the assay could be easily performed in the laboratory. Furthermore, we used the thermal stability as a measure for kinetic stability, as also discussed elsewhere ([@CWU047C35]; [@CWU047C42]). We always included a *P. pastoris* strain expressing the unmutated wild-type (wt) HRP C1A in the screening experiments as control. Although we obtained slightly different results for the wt depending on the screening round, we included the average values for growth, protein production, enzyme activity and thermal stability in Table [I](#CWU047TB1){ref-type="table"} for comparison. Based on the determined specific activity and thermal stability, we chose the most suitable mutation at the single N-glycosylation sites. Except for N13S all the produced HRP glyco-variants showed catalytic activity; however, replacement of Asn by Gln never turned out to be the most suitable mutation at any of the eight N-glycosylation sites. Since we did not measure any detectable extracellular protein content for N13S either, we speculate that this mutation caused problems in protein folding and/or secretion, a phenomenon described before ([@CWU047C53]; [@CWU047C17]; [@CWU047C18]; [@CWU047C54]). Interestingly, we observed significant differences in enzyme activity and stability depending on the introduced mutation (Table [I](#CWU047TB1){ref-type="table"}), and identified three mutations which had been described before, namely at positions N13 and N268 ([@CWU047C2]) and N255 ([@CWU047C29]), respectively. Table I.Results of screening experiments to identify the most suitable mutation at the single N-glycosylation sites of HRP C1AMutationResults after 96 h of inductionChosen mutationOD~600~Cat. activity (U mL^−1^)Protein content (mg mL^−1^)Spec. activity (U mg^−1^)Residual activity after 4 h at 60°C (%)wt25.27.50.1348.475.0N13D31.80.690.097.2927.0→N13DN13Q42.30.740.089.1010.5N13S35.1--------N57D31.40.770.117.0053→N57SN57Q23.42.480.1319.143N57S30.37.200.1355.474N158D32.76.110.2326.6100→N158DN158Q34.10.490.371.3281.8N158S30.00.870.136.2390.8N186D36.80.100.091.0643.1→N186DN186Q47.60.070.100.700N186S46.20.140.091.6036.2N198D21.312.10.2353.168.1→N198DN198Q19.74.310.2220.134.1N198S25.11.250.225.8420.5N214D17.95.030.1146.646.1→N214SN214Q18.14.920.1339.041.5N214S14.23.170.1225.696.0N255D13.67.240.1353.966.5→N255DN255Q14.28.590.1848.378.8N255S11.95.490.1535.974.9N268D13.60.560.272.0770.6→N268DN268Q12.90.400.261.5471.0N268S12.60.430.321.3454.0

Physiological strain characterization in the bioreactor {#s2b}
-------------------------------------------------------

The different *P. pastoris* strains carrying the respective mutated HRP gene were physiologically characterized in single dynamic batch cultivations in the controlled environment of a bioreactor. After exhaustion of glycerol which was indicated by an increase in the off-gas signal, a 0.5% (v/v) methanol adaptation pulse was applied which was followed by several, subsequent 1.0% (v/v) methanol pulses (an example for this procedure is illustrated for the *P. pastoris* strains expressing the wt enzyme and variant N57S in Figure [1](#CWU047F1){ref-type="fig"}, while illustrations for the other strains are shown in [Supplementary data, Figure S1](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cwu047/-/DC1)). This dynamic strategy has repeatedly proven to be a very efficient method to physiologically characterize *P. pastoris* strains in a fast and simple manner ([@CWU047C6],[@CWU047C7]; [@CWU047C22]; [@CWU047C52]). Fig. 1.Batch cultivation of a *P. pastoris* CBS7435 Mut^S^ strain carrying either the unmutated HRP C1A gene (designated as "wt") or the glyco-variant HRP C1A N57S. A1, batch cultivation with methanol pulses of wt; B1, batch cultivation with methanol pulses of N57S. Solid black line, carbon dioxide evolution rate (CER); gray square, specific substrate uptake rate (*q*~s~). A2, calculated yields of wt; B2, calculated yields of N57S. Gray triangle, carbon dioxide yield (*Y*~CO2/S~); black dot, biomass yield (*Y*~X/S~).

In Table [II](#CWU047TB2){ref-type="table"}, the determined strain characteristic parameters of all the strains are summarized. Apparently, the introduction of the respective recombinant HRP C1A gene had an impact on the physiology of the *P. pastoris* strains. Although the majority of the strains showed similar maximum specific growth rates on glycerol (*μ*~max\ gly~) between 0.24 and 0.28 h^−1^, the strain carrying the gene HRP C1A N13D showed a nearly 1.3-fold higher *μ*~max\ gly~. This effect was even more pronounced with respect to the specific methanol uptake rate during the adaptation pulse (*q*~s\ adapt~). Surprisingly, when we calculated the average-specific methanol uptake rate during the consecutive 1% (v/v) methanol pulses (*q*~s\ average\ MeOH~), we observed striking differences between all the strains. One can speculate that the reason for the altered strain physiology lies in the produced HRP glyco-variant itself, since it is known that N-glycosylation can influence protein folding and protein production and thus might affect cell physiology ([@CWU047C53]; [@CWU047C17]; [@CWU047C18]; [@CWU047C54]). However, as shown in Table [II](#CWU047TB2){ref-type="table"}, the amount of total extracellular protein for each strain at the end of the dynamic batch cultivation was basically the same, indicating that the single mutations did not cause significant problems in protein folding or secretion. We also analyzed the cell-free cultivation broths on SDS gels and obtained the same pattern of protein bands at comparable intensity (graphs not shown). Thus, apparently not the mutated product but rather the locus of the respective introduced gene in the yeast genome had a significant influence on the methanol metabolism of the cells. This influence is also obvious in both yield coefficients (biomass yield, *Y*~X/S~; carbon dioxide yield, *Y*~CO2/S~). However, we did not investigate the exact locus of gene integration for the single strains in more detail. Closing C-balances for all cultivations confirm the accuracy of the calculated strain specific parameters. It is remarkable that although we used the same *P. pastoris* strain CBS7435 Mut^S^, the same vector and basically the same gene except for single point mutations, we obtained physiologically diverging strains. This actually underlines the importance of a detailed physiological strain characterization using the dynamic method applying methanol pulses, especially if subsequent fed-batch cultivations for protein production are envisioned. Table II.Strain characteristic parameters determined for recombinant *P. pastoris* strains harboring either the wt HRP C1A gene or a glyco-variant thereof and the amount of total extracellular protein at the end of cultivationStrain*μ*~max~ ~gly~ (h^−1^)*Δ*~time\ adapt~ (h)*q*~s\ adapt~ (mmol g^−1^ h^−1^)*q*~s~ ~average\ MeOH~ (mmol g^−1^ h^−1^)*Y*~X/S~ (C~mol~ C~mol~^−1^)Y~CO2/S~ (C~mol~ C~mol~^−1^)C-balanceProtein (mg mL^−1^)wt0.27711.10.2690.3700.0130.920.930.08N13D0.3308.70.3170.5920.0630.880.950.08N57S0.24512.80.2160.4090.0270.951.020.09N158D0.25113.50.2110.3040.0651.001.070.09N186D0.26813.10.2110.2730.0191.001.020.10N198D0.2448.30.2920.3720.0220.900.960.08N214S0.26714.40.2190.2130.0120.950.950.08N255D0.2538.40.2910.5370.0060.961.000.11N268D0.25814.40.2530.2560.0381.001.040.08

Protein purification {#s2c}
--------------------

After cultivation, the respective HRP glyco-variant was purified from the cell-free cultivation broth using a previously reported two-step flow-through strategy ([@CWU047C43]; [@CWU047C24]). Total protein content and enzymatic activity were determined in the flow-through and the eluates and the respective recovery yield of HRP activity in percentage (*R*%) and the purification factor (PF) were calculated for each single purification step (Table [III](#CWU047TB3){ref-type="table"}). Table III.Results of the two-step purification approach for HRP C1A applying HCIC and AEC both operated in flow-through modeVariantHCICAECCombinedSpec. activity (U mg^−1^)*R*% total*R*% FTPF*R*% total*R*% FTPF*R*%PFwt83.683.61.9585.977.13.4664.56.7248N13D91.591.52.9485.624.57.9222.423.3689N57S80.780.42.7086.270.93.3256.39.0461N158D53.853.61.8590.175.05.0240.29.3167N186D86.886.81.4891.457.110.249.615.1198N198D51.351.11.3084.050.41.8925.82.5114N214S82.482.31.6694.445.34.5337.37.5113N255D94.994.92.9596.475.46.5971.619.4236N268D94.794.73.4382.074.94.2170.914.4274

After hydrophobic charge induction chromatography (HCIC), we recovered \>80% of wt HRP C1A and of most enzyme variants except for N158D and N198D. In agreement with our previous observations ([@CWU047C43]; [@CWU047C23]), the whole activity was found in the flow-through. The remaining 5--20% of the enzymes did not elute from the column under the conditions applied, which actually proofs the existence of a variety of enzyme species in the cultivation broth differing in glycosylation and thus a varying degree of interaction with the resin. Interestingly, for glyco-variant N158D and N198D, we only recovered 50% of the enzyme in total, which we also found in the flow-through. Apparently, by mutating these two glycosylation sites and thus reducing the overall amount of surface N-glycosylation, the masking effect thereof was reduced leading to a different HCIC performance for these two enzyme variants. However, compared with the other glycosylation sites we could not identify a particular location of these two sites which could potentially explain this phenomenon ([Supplementary data, Figure S2](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cwu047/-/DC1)). By HCIC, the wt enzyme was purified 2-fold, whereas the success of purification varied between 1.3- and 3.4-fold for the different glyco-variants highlighting the importance of an integrated bioprocess aspect---already little changes of protein properties, as the degree of surface N-glycosylation, might have a significant impact on following unit operations. The difference in the PF for wt HRP C1A compared with previous studies where we achieved a PF of 7.0 ([@CWU047C24]) might be explained by the different cultivation strategies. In our previous study, we cultivated *P. pastoris* in shake flasks, where conditions were not controlled and limitations in nutrients and oxygen occurred, which is why cells were more sensitive to cell lysis. Consequently, more contaminating proteins were found in the cell-free cultivation broth. In the present study, we cultivated the different strains in a bioreactor where parameters, such as pH and temperature, were controlled and thus undesired cell lysis was reduced. Consequently, the cell-free cultivation broth contained less contaminating proteins. This is also obvious when looking at the cell-free cultivation broth before purification, which showed a specific activity of only 20 U mg^−1^ from shake flasks ([@CWU047C24]) but ∼40 U mg^−1^ in the present study.

In the subsequent anion exchange chromatography (AEC) step, we recovered \>80% of the initially applied HRP for all enzyme variants (Table [III](#CWU047TB3){ref-type="table"}). However, the amount of HRP we found in the flow-through vastly differed between the glyco-variants. For the wt enzyme and variants N57S, N158D, N155D and N268D, we found a comparable amount of ∼75% of HRP in the flow-through, whereas for variants N13D, N186D, N198D and N214S, the recovery in the flow-through was only 50% or less. For N13D, we even only found 25% of the enzyme in the flow-through, whereas the rest was found in the eluate together with contaminating proteins. However, when we looked at the location of N13 in comparison to the other glycosylation sites we could not identify a particularity which could explain this phenomenon ([Supplementary data, Figure S2](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cwu047/-/DC1)). This again highlights the importance of the single N-glycosylation sites and the respective surface N-glycosylation for the physicochemical properties of HRP and the applicability of the flow-through chromatography approach. With regard to AEC purification success, we obtained a PF of \>3 for the wt enzyme and similar values for N57S, N214S and N268D. Although we only recovered 25% of the initial amount of N13D in the flow-through, this glyco-variant was purified nearly 8-fold. Also N158D, N186D and N255D were purified with great success (5-, 10- and more than 6-fold, respectively), whereas for variant N198D, a PF of only two was determined in the flow-through.

With respect to the overall purification efficiency for the glyco-variant library of HRP C1A using a two-step flow-through approach, we observed vastly different results (Table [III](#CWU047TB3){ref-type="table"}). The overall recovery of the initial amount of HRP after the two purification steps varied from only 20% to \>70%. Also the obtained total PF varied immensely between 2.5 for variant N198D and \>23 for N13D. Remarkably, these vast differences only originated from single point mutations of HRP C1A and consequent changes in surface N-glycosylation. Hence, for some of these variants, such as for N198D, we recommend to adapt the downstream strategy to obtain an enzyme preparation with higher purity.

Biochemical enzyme characterization {#s2d}
-----------------------------------

After protein purification, the enzyme variants were biochemically characterized. In Table [IV](#CWU047TB4){ref-type="table"}, the kinetic constants for the substrates 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) and H~2~O~2~ are shown. The here presented apparent *K*~m~ of 1.60 mm of the wt HRP C1A preparation for ABTS was higher than the previously published *K*~m~ values of 0.27 and 0.18 mm for C1A preparations from plant and *E. coli*, respectively ([@CWU047C13]). However, in previous studies on recombinant HRP C1A from *P. pastoris*, *K*~m~ values of 0.68 mm ([@CWU047C30]) and 1.01 ([@CWU047C24]) were reported. Apparently, yeast-derived HRP C1A preparations generally have a tendency for a lowered affinity to ABTS compared with preparations from plant and *E. coli*, indicating a crucial role of glycosylation for enzyme activity. Table IV.Kinetic constants of wt HRP C1A and the glyco-variants for the substrates ABTS and H~2~O~2~ as well as thermal stabilityVariantABTSH~2~O~2~*τ*~½~ (min)*K*~m~ (mM)*V*~max~ (U mg^−1^)*V*~max~/*K*~m~ (U mg^−1^ mm^−1^)*K*~m~ (mM)*V*~max~ (U mg^−1^)*V*~max~/*K*~m~ (U mg^−1^ mm^−1^)wt1.6044.227.70.00316.3543320.6N13D2.9047.216.30.00514.7306628.9N57S2.9811338.10.00423.7537838.5N158D3.0816.35.300.00551.710,3423.2N186D4.2477.418.20.0047.63217918.8N198D1.2114.912.30.00319.1579518.5N214S3.4841.111.80.0049.3625316.3N255D1.7251.529.90.00521.6450611.6N268D1.8932.517.20.00310.6364261.9

As shown in Table [IV](#CWU047TB4){ref-type="table"}, the *K*~m~ values of the glyco-variants for ABTS were higher than for the wt, except for variant N198D. Mutating the N-glycosylation sites on the surface of enzyme HRP C1A also affected the reaction rate (Table [IV](#CWU047TB4){ref-type="table"}). Summarizing, in terms of catalytic efficiency with ABTS only variants N57S and N255D showed slightly higher or similar values compared with the wt. A similar effect for glyco-variant N255D had already been described elsewhere ([@CWU047C29]). The other glyco-variants were characterized by an up to 5-fold reduced catalytic efficiency. Interestingly, in the work of [@CWU047C2]) HRP variants N13D and N268D also showed higher catalytic activity compared with the wt. However, Asad et al. used a different reducing substrate as well as different assay conditions, which is why a direct comparison with the present study is not feasible.

We observed similar trends of *K*~m~ and *V*~max~ for the substrate H~2~O~2~, as the majority of HRP glyco-variants showed a reduced catalytic efficiency compared with the wt enzyme (Table [IV](#CWU047TB4){ref-type="table"}). In fact, N57S was the only glyco-variant showing similar or even higher catalytic efficiency with both substrates compared with the wt. The Michaelis--Menten kinetics for the wt enzyme and for variant N57S for both substrates is exemplarily shown in Figure [2](#CWU047F2){ref-type="fig"}, whereas illustrations for the other enzyme variants are shown in the [Supplementary data, Figure S3](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cwu047/-/DC1). Fig. 2.Michaelis--Menten kinetics of the unmutated wt HRP C1A and the glyco-variant N57S for ABTS and H~2~O~2~. (**A**) Kinetics for ABTS, (**B**) kinetics for H~2~O~2~. Black dots, N57S; gray squares, wt.

To potentially explain the observed effects of the mutations on the surface of the enzyme on the catalytic activity, we determined the distance of the respective N-glycosylation site to the amino acid His170, which is linked to the heme group in the active site (Figure [3](#CWU047F3){ref-type="fig"}). However, we were not able to identify a direct correlation between the distance of the N-glycosylation site to the active site and observed changes in catalytic activity. Only resolving the crystal structures of the single HRP C1A glyco-variants and the subsequent analysis of structure--function relationships could potentially explain the observed effects of the respective mutation on the catalytic behavior. Fig. 3.Distances of the N-glycosylation sites on the surface of HRP C1A to the heme-binding site His170 in the active site.

Finally, we also tested the enzymes for thermal stability, since it is known that mutating N-glycosylation sites on the surface of proteins might affect stability ([@CWU047C2]). In order to investigate if the protein concentration affects thermal stability, as described elsewhere ([@CWU047C2]), two different concentrations, i.e., 0.01 and 0.02 mg mL^−1^, of the wt HRP were tested. In fact, we observed a huge difference in the half-life time at 60°C, which we determined with 20.6 min for the less concentrated protein solution and with 121 min for the more concentrated one. Consequently, we normalized all the different HRP glyco-variant solutions to a concentration of 0.01 mg mL^−1^ before heat treatment. Interestingly, we found striking differences in the thermal stability of the enzyme glyco-variants (Table [IV](#CWU047TB4){ref-type="table"}). For N158D, N214S and N255D stability was significantly reduced, whereas N186D and N198D showed half-life times comparable to the wt. Interestingly, N13D and N57S showed a higher thermal stability and N268D had an even 3-fold higher half-life time (τ~½~) than the fully glycosylated enzyme. Comparable observations for variants N13D and N268D were also made by [@CWU047C2]). The differences between the determined half-life times in this study compared with the study of Asad et al., who determined the stability at 50°C, can be explained by differences in the assay conditions. Whereas [@CWU047C3]) used a 200 mm phosphate buffer, we only used a 50 mm phosphate buffer, which is known to positively affect HRP stability. Summarizing, it is remarkable that mutating glycosylation sites of a protein and thus reducing its overall glycosylation pattern does not only reduce protein stability but might also increase it.

### Glycosylation analysis {#s2d1}

To prove the absence of surface glycosylation on the respective mutated N-glycosylation site, we exemplarily performed glycosylation analysis for the glyco-variant N57S by digesting the protein with either chymotrypsin or trypsin and subsequently analyzing the peptides by liquid-chromatography mass spectrometry. Furthermore, aliquots of the chymotryptic digest were incubated with PNGase A and released glycans were analyzed by mass spectrometry (Figure [4](#CWU047F4){ref-type="fig"}). The success of mutating Asn57 to a non-glycosylated Ser was confirmed by mass spectrometric analysis of chymotryptic peptides. We clearly see the absence of surface N-glycosylation on N57S (Figure [4](#CWU047F4){ref-type="fig"}). Fig. 4.Verification of the mutated peptide LD^57^STTSF by MS. (A) The extracted ion chromatograms for the mass of LDSTTSF (\[M + H\]^+^ 770.36 Da) in N57S HRP. The mutant exhibited the relevant peak, whose identity was confirmed by CID fragmentation as shown in (B). B-fragments with loss of H~2~O are designated as b^o^ fragments.

Combination of mutations {#s2e}
------------------------

To potentially obtain an enzyme variant without any N-glycosylation, we combined all the eight mutations described in chapter Screening procedure (hereafter called "mutant"). The resulting *P. pastoris* strain was again cultivated in a batch with consecutive methanol pulses for physiological strain characterization (Table [V](#CWU047TB5){ref-type="table"}). Again, we observed very different strain characteristic parameters, although we used the same *P. pastoris* strain CBS7435 Mut^S^, the same vector and basically the same gene except for eight point mutations. Closing C-balances for both cultivations confirm the accuracy of the calculated strain specific parameters. In contrast to the strain carrying the wt HRP C1A gene, we were not able to detect any HRP activity in the cell-free cultivation broth for the strain carrying the mutated gene. Only after ultrafiltration and 20-fold concentration of the cultivation broth, we were able to measure activity for the mutated HRP C1A glyco-variant. We concentrated the enzyme further and diafiltrated it before we determined the catalytic constants with ABTS and H~2~O~2~ as well as thermal stability (Table [VI](#CWU047TB6){ref-type="table"}). As shown in Table [VI](#CWU047TB6){ref-type="table"}, the combination of all eight mutations to obtain a HRP C1A variant without any *N*-glycans resulted in an enzyme variant with extremely reduced catalytic efficiency and thermal stability. Although the affinity towards ABTS basically remained the same, the catalytic activity was reduced nearly 300-fold. The effects for H~2~O~2~ were even more severe, as *K*~m~ was increased \>8-fold and *V*~max~ decreased \>100-fold resulting in a nearly 1000-fold reduced catalytic efficiency. As judged by SDS--PAGE analysis, the size of this variant was significantly reduced compared with the glycosylated wt enzyme (figure not shown). However, since catalytic activity and stability were that low, making this variant not useful for medical applications, we did not analyze the surface N-glycosylation of this glyco-variant in more detail. Table V.Strain characteristic parameters determined for recombinant *P. pastoris* strains harboring either the wt HRP C1A gene or a variant where all the eight N-glycosylation sites were mutated (mutant)Strain*μ*~max\ gly~ (h^−1^)*Δ*~time\ adapt~ \[h\]*q*~s\ adapt~ (mmol g^−1^ h^−1^)*q*~s\ average\ MeOH~ (mmol g^−1^ h^−1^)*Y*~X/S~ (C~mol~ C~mol~^−1^)*Y*~CO2/S~ (C~mol~ C~mol~^−1^)C-balanceProtein (mg mL^−1^)Wt0.27711.10.2690.3700.0130.920.930.08Mutant0.2224.70.6600.8820.1530.810.970.10 Table VI.Kinetic constants of wt HRP C1A and the variant where all the eight N-glycosylation sites were mutated (mutant) for the substrates ABTS and H~2~O~2~ as well as thermal stabilityVariantABTSH~2~O~2~*τ*~½~ (min)*K*~m~ (mM)*V*~max~ (U mg^−1^)*V*~max~/*K*~m~ (U mg^−1^ mm^−1^)*K*~m~ (mM)*V*~max~ (U mg^−1^)*V*~max~/*K*~m~ (U mg^−1^ mm^−1^)Wt1.6044.227.70.00316.3543320.6Mutant1.440.150.100.0260.145.383.2

Summarizing, enzyme engineering describes a valid approach to obtain active HRP C1A variants with a reduced amount of surface N-glycosylation. Although an enzyme variant where all the eight N-glycosylation sites were mutated hardly showed catalytic activity and thus does not describe a meaningful tool for medical applications, the here described glyco-library of HRP C1A describes a very useful basis for further enzyme engineering approaches. Studies, where we only combine up to four mutations, namely N13D, N57S, N255D and N268D, and then express these variants in a *P. pastoris OCH*1 knockout strain ([@CWU047C23]) to obtain a HRP C1A variant useful for targeted cancer treatment are currently ongoing.

Material and methods {#s3}
====================

Chemicals {#s3a}
---------

Enzymes were purchased from Fermentas GmbH (Vienna, Austria). ABTS diammonium salt was obtained from Sigma--Aldrich Handels GmbH (Vienna, Austria). Difco™ yeast nitrogen base w/o amino acids (YNB), Bacto™ tryptone and Bacto™ yeast extract were obtained from Becton Dickinson and Company (Schwechat, Austria). Zeocin™ was obtained from Invitrogen (Vienna, Austria). D-Biotin was obtained from Fluka Chemia AG (St. Gallen, Switzerland). All other chemicals were purchased from Carl Roth GmbH & Co. KG (Karlsruhe, Germany).

Strain and gene {#s3b}
---------------

*P. pastoris* CBS7435 Mut^S^ ([@CWU047C6],[@CWU047C7]; [@CWU047C22]; [@CWU047C52]; [@CWU047C23]; [@CWU047C44]) and vector pPpT4_S harboring the HRP isoenzyme C1A, which was codon-optimized for high-level expression in *P. pastoris* ([@CWU047C22]), were used in this study. The codon table described in [@CWU047C1]) was applied for codon optimization. Secretion of HRP C1A to the cultivation broth was facilitated by an N-terminally fused prepro-signal sequence of the *S. cerevisiae* alpha-factor.

Site-directed mutagenesis {#s3c}
-------------------------

The eight Asn, representing the glycosylation sites of HRP C1A, were mutated to either Asp, Gln or Ser, which are amino acids providing a certain structural similarity to Asn, by site-directed mutagenesis and subsequent digestion with DpnI ([@CWU047C27]). The mutagenic PCR was performed as: 98°C for 30 s; then 10 cycles of 98°C for 10 s, 57°C for 20 s, 72°C for 1 min---10 cycles of 98°C for 10 s, 60°C for 20 s, 72°C for 1 min---10 cycles of 98°C for 10 s, 63°C for 20 s, 72°C for 1 min; with a final incubation at 72°C for 10 min. Each reaction contained 1× HF buffer (Fermentas), 0.1 μg of plasmid DNA, 2.5 U *Phusion* DNA polymerase (Fermentas), 10 μm of each dNTP and 5 pmol of each primer in a total volume of 50 µL. All primers are listed in Table [VII](#CWU047TB7){ref-type="table"} and were purchased from Microsynth (Vienna, Austria). Table VII.Oligonucleotide primers to mutate the eight Asn residues of the enzyme HRP C1A, which act as N-glycosylation sites, to either Asp, Gln or SerN-siteNameSequence (5′→3′)N13N13D_fwdAAC TCT TGT CCT *GAT* GTG TCC AAC ATCN13Q_fwdAAC TCT TGT CCT *CAG* GTG TCC AAC ATCN13S_fwdAAC TCT TGT CCT *AGT* GTG TCC AAC ATCN13_revAGG ACA AGA GTT ATC GTA GAA GGT TGG AGTN57N57D_fwdTCC ATC TTG CTG GAC *GAC* ACT ACC TCN57Q_fwdTCC ATC TTG CTG GAC *CAG* ACT ACC TCN57S_fwdTCC ATC TTG CTG GAC *AGC* ACT ACC TCN57_revGTC CAG CAA GAT GGA AGC ATC ACA ACCN158N158D_fwdC AGA AAC GTT GGT CTT *GAC* AGA TCA TCCN158Q_fwdC AGA AAC GTT GGT CTT *CAG* AGA TCA TCCN158S_fwdC AGA AAC GTT GGT CTT *AGC* AGA TCA TCCN158_revAAG ACC AAC GTT TCT GAA AGA GTC TTT CAA TTGN186N186D_fwdATG GAT CGT CTG TAC *GAC* TTC TCT AAC ACN186Q_fwdATG GAT CGT CTG TAC *CAG* TTC TCT AAC ACN186S_fwdATG GAT CGT CTG TAC *AGC* TTC TCT AAC ACN186_revGTA CAG ACG ATC CAT GAT GAA TCT ACA TTG GTTN198N198D_fwdCCA GAT CCT ACT CTG *GAC* ACC ACT TACN198Q_fwdCCA GAT CCT ACT CTG *CAG* ACC ACT TACN198S_fwdCCA GAT CCT ACT CTG *AGC* ACC ACT TACN198_revCAG AGT AGG ATC TGG CAA ACC GGN214N214D_fwdCCA CTT AAC GGA *GAC* CTG TCT GCN214Q_fwdCCA CTT AAC GGA *CAG* CTG TCT GCN214S_fwdCCA CTT AAC GGA *AGC* CTG TCT GCN214_revTCC GTT AAG TGG GCA CAA ACC TCN255N255D_fwdTTG TTC TCC TCT CCT *GAC* GCT ACT GATN255Q_fwdTTG TTC TCC TCT CCT *CAG* GCT ACT GATN255S_fwdTTG TTC TCC TCT CCT *AGC* GCT ACT GATN255_revAGG AGA GGA GAA CAA CTC CTG GTCN268N268D_fwdG AGA TCC TTC GCA *GAC* TCC ACT CAAN268Q_fwdG AGA TCC TTC GCA *CAG* TCC ACT CAAN268S_fwdG AGA TCC TTC GCA *AGC* TCC ACT CAAN268_revTGC GAA GGA TCT CAC CAA TGG AAT G[^1]

After PCR, the methylated template DNA was degraded by digestion with 10 U of DpnI at 37°C for at least 3 h. The remaining PCR products were purified using the QIAquick PCR purification kit (QIAGEN, Vienna, Austria) and 5 μL of each purified PCR product were transformed into electro-competent *E. coli* TOP10 F′ cells. The successful introduction of the desired mutation and the absence of further mutations were confirmed by DNA sequencing (Microsynth). Transformation of ∼2 µg SwaI-linearized pPpT4_S plasmid DNA harboring the respective mutated HRP C1A gene ([Supplementary data, Figure S4](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cwu047/-/DC1)) into *P. pastoris* was done as described by [@CWU047C28]. Stable transformants were generated via homologous recombination between the linearized plasmid DNA and genomic yeast DNA. Selection of successfully transformed clones was performed on yeast extract peptone dextrose medium (YPD; 10 g L^−1^ yeast extract, 20 g L^−1^ peptone, 20 g L^−1^ glucose, 20 g L^−1^ agar) supplemented with 100 mg L^−1^ Zeocin.

Screening procedure {#s3d}
-------------------

Screening of five randomly picked *P. pastoris* transformants per mutation was done in 1000 mL shaking flasks. We also included a *P. pastoris* CBS7435 Mut^S^ strain carrying the unmutated HRP C1A gene (henceforth designated as "wt") as well as an untransformed *P. pastoris* CBS7435 Mut^S^ strain as negative control, resulting in a total of 17 shaking flasks per screening experiment. First the clones were cultivated in 10 mL buffered glycerol complex medium supplemented with 100 mg L^−1^ Zeocin (BMGY_Zeo; 10 g L^−1^ yeast extract; 20 g L^−1^ peptone; 3.4 g L^−1^ YNB w/o amino acids and ammonia sulfate, 10 g L^−1^ (NH~4~)~2~SO~4~, 400 mg L^−1^ biotin; 1 g L^−1^ glycerol; 0.1 M potassium phosphate buffer, pH 6.0) in 100 mL shaking flasks at 30°C and 230 rpm overnight. The next day the OD~600~ was measured, an appropriate aliquot of the culture was taken, and after centrifugation the cells were resuspended in selective buffered methanol complex medium supplemented with 100 mg L^−1^ Zeocin (BMMY_Zeo; 10 g L^−1^ yeast extract; 20 g L^−1^ peptone; 3.4 g L^−1^ YNB w/o amino acids and ammonia sulfate, 10 g L^−1^ (NH~4~)~2~SO~4~, 400 mg L^−1^ biotin; 0.5% methanol; 0.1 M potassium phosphate buffer, pH 6.0) to an OD~600~ of 1.0. The cells were again cultivated at 30°C and 230 rpm. Every day, 1% (v/v) methanol was pulsed to the culture and a 1 mL sample was taken, analyzed for optical density (OD~600~), catalytic activity and protein content. The catalytic activity of HRP was measured using an ABTS assay in a CuBiAn XC enzymatic robot (Bielefeld, Germany). Ten microliters of sample were mixed with 140 µL 1 mm ABTS solution (50 mm KH~2~PO~4~, pH 6.5). The reaction mixture was incubated at 37°C for 5 min before the reaction was started by the addition of 20 µL 0.078% H~2~O~2~ (v/v). Changes in absorbance at 415 nm were measured for 80 s and rates were calculated. The standard curve was prepared using a commercially available HRP preparation (Type VI-A; Sigma--Aldrich) in the range from 0.02 to 2.0 U mL^−1^. Protein concentrations were determined at 595 nm by the Bradford assay using the Sigma--Aldrich Protein Assay Kit with bovine serum albumin as standard in the range of 0.2--1.2 mg mL^−1^.

After 96 h of induction, the HRP glyco-variants in the cell-free supernatants were tested for thermal stability. Therefore, aliquots of 1 mL were incubated in a waterbath at 60°C for up to 4 h, before the samples were centrifuged (14,000 rpm; 10 min) and the supernatants were analyzed for remaining HRP activity. These values were then compared with the initial activity before heat treatment. Based on activity and stability measurements, the most suitable mutation at a respective N-glycosylation site was chosen and the corresponding *P. pastoris* strain was physiologically characterized in the bioreactor. Before bioreactor cultivation, the presence of the correctly mutated HRP gene in the respective *P. pastoris* transformant was verified by colony PCR using the primers AOX_fwd (5′-ACTCCAACCTTCTACGATAACTC-3′) and AOX_rev (5′-ACTGTGTCATGTGCTGACC-3′) and subsequent sequencing (Microsynth).

Strain characterization in the bioreactor {#s3e}
-----------------------------------------

### Culture media {#s3e1}

Precultures were done in yeast nitrogen base medium with 100 mg L^−1^ Zeocin (YNBM_Zeo; 3.4 g L^−1^ YNB w/o amino acids and ammonia sulfate, 10 g L^−1^ (NH~4~)~2~SO~4~, 400 mg L^−1^ biotin, 20 g L^−1^ glucose, 0.1 M potassium phosphate buffer, pH 6.0). Batch cultivations were performed in basal salt medium (26.7 mL L^−1^ 85% phosphoric acid, 1.17 g L^−1^ CaSO~4~ · 2H~2~O, 18.2 g L^−1^ K~2~SO~4~, 14.9 g L^−1^ MgSO~4~ · 7H~2~O, 4.13 g L^−1^ KOH, 40 g L^−1^ glycerol, 0.2 mL L^−1^ Antifoam Struktol J650, 4.35 mL L^−1^ PTM1, NH~4~OH as N-source). Trace element solution (PTM1) was made of 6.0 g L^−1^ CuSO~4~ · 5H~2~O, 0.08 g L^−1^ NaI, 3.0 g L^−1^ MnSO~4~ · H~2~O, 0.2 g L^−1^ Na~2~MoO~4~ · 2H~2~O, 0.02 g L^−1^ H~3~BO~3~, 0.5 g L^−1^ CoCl~2~, 20.0 g L^−1^ ZnCl~2~, 65.0 g L^−1^ FeSO~4~ · 7H~2~O, 0.2 g L^−1^ biotin, 5 mL L^−1^ H~2~SO~4~. Induction was carried out in presence of 1 mm Δ-aminolevulinic acid. The concentration of the base NH~4~OH was determined by titration with 0.25 M potassium hydrogen phthalate.

Experimental procedure {#s3f}
----------------------

### Preculture {#s3f1}

Frozen stocks (−80°C) were cultivated in 100 mL YNBM in 1000 mL shake flasks at 30°C and 230 rpm. The grown preculture was transferred aseptically to the respective culture vessel. The inoculation volume was 10% of the final starting volume.

### Batch cultivation {#s3f2}

Batch cultivations were carried out in either a 3 L or a 5 L working volume glass bioreactor (Infors, Bottmingen, Switzerland). Basal salt medium was sterilized in the bioreactor and pH was adjusted to pH 5.0 by using concentrated NH~4~OH solution after autoclaving. Sterile filtered trace elements were transferred to the reactor aseptically. Dissolved oxygen (dO~2~) was measured with a sterilizable dO~2~ electrode (Visiferm™, Hamilton, Bonaduz, Switzerland). The pH was measured with a sterilizable electrode (Easyferm™, Hamilton, Bonaduz, Switzerland) and maintained constant with a PID controller using NH~4~OH solution (1--2 M). Base consumption was determined gravimetrically. Cultivation temperature was set to 30°C and agitation was fixed to 1200 rpm. The culture was aerated with 1.0 Vvm dried air and off-gas of the culture was measured by using an infrared cell for CO~2~ and a paramagnetic cell for O~2~ concentration (Servomax, Hyderabad, India). Temperature, pH, dO~2~, agitation as well as CO~2~ and O~2~ in the off-gas were measured online and logged in a process information management system (Lucullus, Biospectra, Schlieren, Switzerland). After the complete consumption of the substrate glycerol, indicated by an increase of dO~2~ and a drop in off-gas activity, the first methanol pulse of a final concentration of 0.5% (v/v) was conducted with methanol supplemented with 12 mL L^−1^ PTM1. Following pulses were performed with 1% methanol/PTM1 (v/v) (Figure [2](#CWU047F2){ref-type="fig"}). For each pulse, two samples were taken to determine the concentrations of substrate and product, as well as dry cell weight to calculate specific rates and yields.

Analysis of growth and expression parameters {#s3g}
--------------------------------------------

Dry cell weight was determined by centrifugation of 5 mL culture broth (5000 rpm, 4°C, 10 min) in a laboratory centrifuge (Sigma 4K15, rotor 11156), washing the pellet twice with 5 mL deionized water and subsequent drying at 105°C to a constant weight.

Substrate concentrations {#s3h}
------------------------

Concentrations of methanol were determined in cell-free samples by HPLC (Vienna, Austria) equipped with an ion-exchange column (Supelcogel C-610H Sigma--Aldrich) and a refractive index detector (Agilent Technologies). The mobile phase was 0.1% H~3~PO~4~ with a constant flow rate of 0.5 mL min^−1^ and the system was run isocratic at 30°C. Calibration was done by measuring standard points in the range from 0.1 to 10 g L^−1^ methanol. Measurements of biomass, product and substrate concentration were executed in duplicates.

Protein purification {#s3i}
--------------------

After bioreactor cultivation, the cell-free cultivation broth was diafiltrated for subsequent HCIC using a Centramate 500S TFF system (PALL, Vienna, Austria) with a 10 kDa MWCO membrane. The buffer was HCIC-A (500 mm NaCl, 20 mm NaOAc, pH 6.0) and the protein solution was concentrated to a final volume of 40--50 mL. All further steps of concentration and buffer change were performed using Amicon Ultra-15 Centrifugal Filter Units with 10 kDa MWCO (Merck Millipore; Vienna, Austria). The HCIC resin MEP HyperCel™ was obtained from PALL and HCIC was performed in flow-through mode: a column containing 25 mL of MEP HyperCel™ resin was equilibrated with at least 4 column volumes (CV) of buffer HCIC-A. Forty to 50 mL concentrated HRP solution in HCIC-A were loaded onto the column which was then washed with at least 5 CV of HCIC-A at a flow rate of 55 cm h^−1^. Then a step elution to 100% buffer HCIC-B (1.0 M NaCl, 20 mm NaOAc, pH 8.0) was performed. After elution, the column was washed with 5 CV 0.8 M NaOH before it was stored in EtOH 20%, 1.0 M NaCl. During all the different steps, fractions of 10 mL were collected and analyzed for protein content and catalytic activity.

HCIC flow-through fractions showing HRP activity were pooled, concentrated and rebuffered in AEC-A (50 mm Tris--HCl, pH 8.0) for subsequent AEC using an 8 mL CIM^®^-DEAE monolithic column ([@CWU047C24]) (BIAseparations, Ajdovščina, Slovenia). The column was equilibrated with 5 CV of AEC-A at a flow rate of 16.8 cm h^−1^. Diafiltrated post-HCIC pools were subsequently loaded onto the AEC column at an average linear flow rate of 16.8 cm h^−1^ before a post-load wash with 5 CV of AEC-A was performed. Elution was performed in a single step from 0 to 100% AEC-B (50 mm Tris--HCl, 1.0 M NaCl, pH 8.0). The column was washed with 5 CV of a 1 M NaOH/1 M NaCl solution at an average linear flow rate of 33.6 cm h^−1^ for column recovery, before the column was stored in 20% EtOH.

The efficiency of each purification step was evaluated by determining the PF and the recovery yield of HRP activity in percentage (*R*%). PF and *R*% were calculated by Eqs (1) and (2) ([@CWU047C24]). The suffixes "pre" and "post" indicate the respective values before and after a purification step. $$\text{PF} = {\frac{\text{specific}\;\text{activit}\text{y}_{post}}{\text{specific}\;\text{activit}\text{y}_{pre}},}$$ $$R\% = 100 \times {\frac{\text{volumetric}\;\text{activit}\text{y}_{post}\; \times \text{volum}\text{e}_{post}}{\text{volumetric}\;\text{activit}\text{y}_{pre} \times \text{volum}\text{e}_{pre}}.}$$ Finally, the pooled active fractions after AEC were diafiltrated in 50 mm potassium phosphate buffer, pH 6.5, and concentrated to a volume of ∼1.5 mL for the subsequent biochemical characterization.

Biochemical enzyme characterization {#s3j}
-----------------------------------

Biochemical characterization of the purified HRP glyco-variants included the determination of the basic kinetic parameters *K*~m~ and *V*~max~ for the two substrates H~2~O~2~ and ABTS in a spectrophotometer UV-1601 from Shimadzu (Korneuburg, Austria). The reaction mixture with a final volume of 1.0 mL contained 20 µL of HRP glyco-variant, 50 mm potassium phosphate buffer, pH 6.5, and either varying concentrations of ABTS (0.01--10 mm) and a saturating concentration of H~2~O~2~ of 1.0 mm or varying concentrations of H~2~O~2~ (0.001--1.0 mm) and a saturating concentration of ABTS of 10.0 mm, respectively. The increase in absorption was followed at 420 nm at 30°C for 180 s. Absorption curves were recorded with a software program (UVPC Optional Kinetics software, Shimadzu). The maximum reaction rate (*V*~max~) and the Michaelis constant (*K*~m~) were calculated with the Sigma Plot software (Version 11.0; Systat Software Inc.).

The thermal stability of individual HRP glyco-variants was tested at 60°C. The residual activity towards ABTS was measured after 1, 5, 10, 15, 30, 45, 60, 90 and 120 min of incubation at 60°C in a water bath. Protein concentrations were normalized to 0.01 mg mL to limit possible effects of the different protein concentrations on thermal stability ([@CWU047C2]) and to obtain comparability. Residual activities were plotted versus the incubation time and the half-life times of thermal inactivation at 60°C (τ~½~) were calculated using Eq. (3): $$\tau_{1/2} = {\frac{\text{ln}\; 2}{k_{in}},}$$ *k*~in~ rate of inactivation (slope of the logarithmic residual activity).

### Glycosylation analysis {#s3j1}

Purified HRP sample was buffered in 0.1 M NH~4~HCO~3~ and reduced with dithiothreitol (5 mm) for 45 min at 56°C and alkylated using iodoacetamide (25 mm) at room temperature for 30 min. The protein was precipitated with 4 volumes of acetone for 45 min at −20°C, dried in a vacuum centrifuge and resuspended in 0.1 M NH~4~HCO~3~ buffer to yield a protein concentration of ∼1 µg µL^−1^. Digests were performed overnight with either chymotrypsin or trypsin (Promega, Mannheim, Germany) at 37°C at an enzyme-to-substrate ratio of 1:50 (w/w). The digested peptides were analyzed by liquid-chromatography mass spectrometry as follows: 1 µg of sample was loaded on a BioBasic-18 column (150 × 0.32 mm; 5 µm; Thermo Scientific, Vienna, Austria) and eluted with a gradient from 1 to 60% acetonitrile in 0.3% formic acid buffered to pH 3.0 at flow rate of 6 µL min. Eluted peptides were analyzed on an Ultima Global Q-TOF mass spectrometer (Waters, Manchester, UK) operated in positive-ion mode, which was previously calibrated with a cesium iodide standard in the range of 400--1800 *m/z*. Additionally, the peptide harboring the site N57S within the mutated HRP variant was subjected to collision-induced dissociation MS-MS with Argon as collision gas. Data were manually evaluated and deconvoluted using the Software MassLynx V4.00.00 (Waters).

An aliquot of the chymotryptic digest was heat inactivated and then incubated with 0.03 MU PNGase A (Proglycan, Vienna, Austria) in 50 mm citrate buffer, pH 5.5. Glycans were purified using porous graphitic carbon cartridges (Thermo Scientific) as described ([@CWU047C33]). Glycans were analyzed by mass spectrometry as described in chapter Glycosylation analysis for peptides with the sole divergence of using a 100 × 0.32 mm hypercarb column (Thermo Scientific) and 1 h gradient from 1 to 50% acetonitrile.
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[Supplementary data for this article are available online at http://glycob.oxfordjournals.org/](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cwu047/-/DC1).
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[^1]: The mutation sites are depicted in italics.
